Compare Cigna Corp (CI) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs The Coca-Cola Co K — how do they compare? Cigna Corp trades at $297.81 (market cap $80.25B), while The Coca-Cola Co K trades at $82.59 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 4.5× Cigna Corp's market cap, and The Coca-Cola Co K pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| CI | KO | |
|---|---|---|
Market Cap | $80.25B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $311.00 | $84.25 |
52-Week Low | $244.41 | $65.67 |
Enterprise Value | $103.35B | $387.52B |
Dividend Yield | 2.06% | 2.55% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
Coca-Cola (KO) trades at $82.45, down 2.14% on the day, with a bullish technical signal from moving averages and support near $82. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.86 exceeding expectations. Revenue grew to $47.94 billion in 2025, and net income margin improved to 27.8%. Analysts maintain a consensus Buy rating with a $89.75 price target, indicating potential upside. Recent news highlights institutional buying and stable demand trends, though regional divergences exist.
The outlook for KO remains positive, supported by consistent dividend payments—64 consecutive years of increases—and robust profitability metrics like a 45.8% ROE. Risks include macroeconomic headwinds impacting Asian markets and high valuation multiples (P/E of 26.13). Institutional sentiment is bullish, with 60% of analysts recommending Buy. The stock offers a reliable income stream but faces pressure from currency fluctuations and competitive beverage markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
